|
|
|
|
Alkermes Retains Neutral Rec
We maintain our Neutral rating on Alkermes, Inc.(ALKS) with a price target of $11.50. Alkermes is a drug delivery biotech company which uses its proprietary specialized drug delivery technologies to develop drugs for the treatment of central nervous system...
|
|
|
Alkermes Retains Neutral Rec
We maintain our Neutral rating on Alkermes, Inc.(ALKS - Alkermes is a drug delivery biotech company which uses its proprietary specialized drug delivery technologies to develop drugs for the treatment of central nervous system (CNS) disorders, alcoholism and...
|
|
|
Alkermes Retains Neutral Rec - Analyst Blog
We maintain our Neutral rating on Alkermes, Inc.( ALKS ) with a price target of $11.50. Alkermes is a drug delivery biotech company which uses its proprietary specialized drug delivery technologies to develop drugs for the treatment of central nervous...
|
|
|
2/8/10 - FDA Approves New Treatment for Type 2 Diabetes
- (NewsRx.com) The U.S.Food and Drug Administration today approved Victoza (liraglutide), a once-daily injection to treat type 2 diabetes in some adults (see also U.S. Food and Drug Administration). Victoza is intended to help lower blood sugar levels...
|
|
|
Novo Nordisk's Victoza receives FDA approval for adults with type 2 diabetes
Novo Nordisk (NVO) announced the U.S.Food and Drug Administration (FDA) approved the new drug application for Victoza (liraglutide [rDNA origin] injection), the first once-daily human glucagon-like peptide-1 (GLP-1) analog for the treatment of type 2...
|
|
|
Diabetes Therapy: Recent findings from Amgen, Inc. highlight research in diabetes therapy
Today's Medical & Research News Diabetes Therapy Recent findings from Amgen, Inc.highlight research in diabetes therapy February 6th, 2010 Printer-Friendly Version City:Thousand Oaks State:California Country:United States Diabetes Therapy Amgen Inc...
|
|
|
Type 2 Diabetes: New research on type 2 diabetes from Omnicare, Inc. summarized
Today's Medical & Research News New research on from Omnicare, Inc.summarized February 5th, 2010 Printer-Friendly Version City:Livonia State:MI Country:United States Dipeptidyl Peptidase Drugs Endocrinology Enzymes Exenatide Glucagon Hydrochloride...
|
|
|
Scott Mendelson, M.D.: New Diabetes Drug May Help Prevent Alzheimer's Disease
On January 26th, the Danish pharmaceutical company, Novo Nordisk, announced that their drug, liraglutide, which will carry the trade name Victoza, has been approved by the U.S.Food and Drug Administration (FDA) for use in the United States for the treatment...
|
|
|
Victoza Gains FDA Approval
Novo Nordisk announced that the US Food and Drug Administration (FDA) has granted marketing authorisation for Victoza for the treatment of type 2 diabetes in adults.Victoza is the brand name approved in the US and Europe for liraglutide, the first once-daily...
|
|
|
Novo Nordisk receives US approval for Victoza (liraglutide)
Novo Nordisk receives US approval for Victoza (liraglutide) for the treatment of type 2 diabetes Novo Nordisk has announced that the US Food and Drug Administration (FDA) has granted marketing authorisation for Victoza for the treatment of type 2 diabetes in...
|
|
|
Novo Nordisk receives US approval for Victoza (liraglutide) for the treatment of type 2 diabetes
Novo Nordisk has announced that the US Food and Drug Administration (FDA) has granted marketing authorisation for Victoza for the treatment of type 2 diabetes in adults.Victoza is the brand name approved in the US and Europe for liraglutide, the first once...
|
|
|
Metformin had small effect on BMI in obese adolescents
Volume 8 Issue 1 Welcome, Guest cancer -stimulating hormone nodules Posted on February 2, 2010 had small effect on BMI in obese adolescents Extended-release metformin appears to cause a small but significant decrease in BMI in obese adolescents without diabetes...
|
|
|
Novo Nordisk Awaits China Approval of Diabetes Treatment
Novo Nordisk (NYSE: NVO) reported that Victoza, its once-daily human glucagon-like peptide-1 (GLP-1) analog for type 2 diabetes, was submitted to the SFDA in August of last year.The news came as Novo Nordisk celebrated approval of the product in the US...
|
|
|
Novo Nordisk's Victoza(R) Receives FDA Approval for Adults With Type 2 Diabetes
Novo Nordisk (NVO) announced that the U.S.Food and Drug Administration (FDA) approved the new drug application for Victoza (liraglutide [rDNA origin] injection), the first once-daily human glucagon-like peptide-1 (GLP-1) analog for the treatment of...
|
|
|
Glucagon-like peptide 1 receptor stimulation as a means of neuroprotection
Glucagon-like peptide 1 (GLP-1) is a relatively recently discovered molecule originating in the so-called L-cells of the intestine.The peptide has insulinotrophic properties and it is this characteristic that has predominantly been investigated. This...
|
|
|
Novo Nordisk Receives US Approval For Victoza (liraglutide) For The Treatment Of Type 2 Diabetes
News Archive [link] Web Wikipedia Medical Dictionary [link] Follow us on: Personalization login | register Diabetes News Main Category: Diabetes Also Included In: Regulatory Affairs / Drug Approvals; Clinical Trials / Drug Trials; Pharma Industry / Biotech...
|
|
|
Novo Nordisk's Victoza Receives FDA Approval for Adults With Type 2 Diabetes
PRINCETON, N.J., Jan.26 /PRNewswire/ -- Novo Nordisk (NVO) announced that the U.S. Food and Drug Administration (FDA) approved the new drug application for Victoza (liraglutide [rDNA origin] injection), the first once-daily human glucagon-like...
|
|
|
FDA Approves New Treatment for Type 2 Diabetes
SILVER SPRING, Md., Jan.25 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Victoza (liraglutide), a once-daily injection to treat type 2 diabetes in some adults. (Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO)...
|
|
|
Changes in Prandial Glucagon Levels after 2-year Treatment with Vildagliptin or Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Metformin Monotherapy
Ahren B et al.The objective was to determine if the dipeptidyl peptidase 4 inhibitor vildagliptin more effectively than the sulfonylurea glimepiride inhibits glucagon levels during meal. Changes in Prandial Glucagon Levels after 2-year...
|
|
|
Ligand Pharmaceuticals acquires Metabasis Therapeutics
Fully funded partnership with Roche to develop new treatments for hepatitis C viral infection utilizing the proprietary HepDirect liver-targeting technology.The lead HepDirect nucleoside, MB11362, was declared a clinical candidate in the second quarter of...
|
|
|
Novo Nordisk's diabetes drug lands FDA approval, with caveats
FURTHER READING Topic abdominal pain glucagon-like peptide-1 pancreatitis Pharmaceutical The FDA has approved liraglutide (Victoza, Novo Nordisk) for its use as treatment in patients with.Liraglutide, a glucagon-like peptide-1 (GLP-1) receptor...
|
|
|
Management of Diabetic Ketoacidosis in the Emergency Department
Fogel N et al.Diabetic ketoacidosis results from deficient insulin action and increased action of hormones such as catecholamines, glucagon, glucocorticoids, and growth hormone, which are produced during stress and which antagonize insulin's actions.
|
|
|
Gestational Diabetes - Reports summarize gestational diabetes research from Amgen, Inc
Learn more about a six-week, no-risk free trial of Immunotherapy Weekly We're a pay-per-view site for premium content.If you'd like to purchase this article, it's only $3.00. Gestational Diabetes Reports summarize gestational diabetes research from Amgen,...
|
|
|
Novo Nordisk gets US approval for New Type2 Diabetes Drug Victoza but with warning
- pharmatimes.com At long last, Novo Nordisk has been given regulatory approval across the Atlantic for its diabetes drug Victoza.The US Food and Drug Administration has given the green light for Victoza (liraglutide), the first once-daily human glucagon...
|
|
|
Victoza Sanctioned for Type 2 Diabetes
TUESDAY, Jan.26 (HealthDay News) -- Victoza (liraglutide) has been approved to treat type 2 diabetes in some adults, the U.S. Food and Drug Administration said in a news release. But the agency warned that the once-daily injection shouldn't be used as an...
|
